EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins. Ozempic topped both SGLT2 drug Invokana from J&J and Novo’s own GLP-1 drug Victoza in head-to-head phase 3 contests.